» Stomach & Pancreatic Cancer

Stomach & Pancreatic Cancer

JANUS1: A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study) (NCT 02117479)
The purpose of this clinical trial is to determine the efficacy of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer.
Website: http://www.clinicaltrials.gov/ct2/show/NCT02117479?term=janus1&rank=1
Principal Investigator: Dr. Peter Graze
Research Staff:   Emily Ross, CCRC – (443)481-4392
                                      Venita Alston Crawford, RN – (443)481-4393

Our Studies